DWM
SRPT icon

Dynasty Wealth Management’s Sarepta Therapeutics SRPT Stock Holding History

Dynasty Wealth Management’s Portfolio SRPT Stock Details SRPT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$300K Buy
13,805
+1,522
+12% +$29.5K ﹤0.01% 290
2025
Q4 		$264K Sell
12,283
-2,050
-14% -$43.2K ﹤0.01% 304
2025
Q3 		$276K Buy
+14,333
New +$256K ﹤0.01% 270

Other funds holding SRPT

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
First Trust Advisors
First Trust Advisors Wheaton, Illinois $140B AUM 27.84% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
EAM
Erste Asset Management Vienna, Austria $10.8B AUM 38.54% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Dynasty Wealth Management's SRPT Position: Q1 2026 in Review

Dynasty Wealth Management increased its Sarepta Therapeutics (SRPT) stake by 12% in Q1 2026, buying an estimated $29.5K and bringing the position to 13,805 shares worth $300K. The position accounts for ﹤0.01% of the portfolio, ranked #290.

Dynasty Wealth Management first reported a position in SRPT in Q3 2025 and has held it in 3 quarters since. 339 funds tracked by Wall St. Rank hold SRPT as of Q1 2026.

  • Dynasty Wealth Management held 13,805 shares of Sarepta Therapeutics worth $300K as of Q1 2026.
  • Dynasty Wealth Management bought 1,522 Sarepta Therapeutics shares in Q1 2026, an estimated $29.5K.
  • Sarepta Therapeutics made up ﹤0.01% of Dynasty Wealth Management's portfolio in Q1 2026, its #290 holding.
  • Dynasty Wealth Management first reported a position in Sarepta Therapeutics in Q3 2025 and has held it in 3 quarters since.
  • 339 funds tracked by Wall St. Rank held Sarepta Therapeutics as of Q1 2026.

Based on Dynasty Wealth Management's 13F filing for Q1 2026, filed 14 May 2026.